首页> 外文期刊>Surgical infections >Comparison of Sequential Intravenous/Oral Ciprofloxacin Plus Metronidazole with Intravenous Ceftriaxone Plus Metronidazole for Treatment of Complicated Intra-abdominal Infections
【24h】

Comparison of Sequential Intravenous/Oral Ciprofloxacin Plus Metronidazole with Intravenous Ceftriaxone Plus Metronidazole for Treatment of Complicated Intra-abdominal Infections

机译:序贯静脉/口服环丙沙星加甲硝唑与静脉注射头孢曲松加甲硝唑治疗复杂性腹腔感染的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Purpose: Intra-abdominal infections are a substantial clinical problem and an important cause of morbidity and death in the hospital. Optimal treatment requires both source control and antibiotic therapy. Sequential intravenous (Ⅳ) to oral therapy may improve patient convenience and reduce total health care costs. In this randomized, double-blind trial, the efficacy of sequential Ⅳ-to-oral ciprofloxacin plus metronidazole was compared with ceftriaxone plus metronidazole in adult patients with complicated intra-abdominal infections. Methods: The trial enrolled 531 patients, who began with Ⅳ therapy. Patients who improved clinically were switched to oral therapy on day three or later. The clinical and bacteriological responses four to six weeks after the end of therapy and the safety of the two regimens were assessed. To maintain blinding, the patients received placebo Ⅳ in the ciprofloxacin group or placebo orally in the ceftriaxone group. A total of 475 patients (235 ciprofloxacin plus metronidazole, 240 ceftriaxone plus metronidazole) were valid for evaluation of efficacy. All patients were included in the safety analysis. Results: Of the patients valid for efficacy, 78% of the ciprofloxacin plus metronidazole group and 81% of the ceftriaxone plus metronidazole group were eligible for a switch to oral therapy. The clinical success rates were 98.9% and 96.9%, respectively, which were statistically equivalent. The clinical success rates for all patients, including those on continuous Ⅳ therapy, were 90.6% and 87.9%. Source control was achieved in more than 90% of the patients. The bacteriological eradication rates were similar in the two groups. Bacterial complications (e.g., surgical site infections, abscesses) were encountered more often in the ceftriaxone plus metronidazole group. Conclusions: Sequential ciprofloxacin plus metronidazole Ⅳ-to-oral therapy was statistically equivalent to ceftriaxone plus metronidazole. The switch to oral therapy with ciprofloxacin plus metronidazole was as effective and safe as continued Ⅳ therapy in patients able to tolerate enteral feeding.
机译:背景与目的:腹内感染是一个重大的临床问题,也是医院发病和死亡的重要原因。最佳治疗需要源控制和抗生素治疗。依序进行静脉(Ⅳ)口服治疗可以改善患者的便利性并降低总体医疗费用。在这项随机,双盲试验中,比较了成人腹腔内感染合并成人时,连续进行Ⅳ至口服环丙沙星联合甲硝唑与头孢曲松联合甲硝唑的疗效。方法:该试验招募了531例开始Ⅳ期治疗的患者。在临床上有所改善的患者在第三天或更晚转为口服治疗。评估治疗结束后四到六周的临床和细菌学反应以及两种方案的安全性。为了维持致盲性,患者接受环丙沙星组的安慰剂Ⅳ或头孢曲松组的口服安慰剂。共有475例患者(235环丙沙星加甲硝唑,240头孢曲松酮加甲硝唑)对疗效进行了评估。所有患者均纳入安全性分析。结果:在有效疗效的患者中,环丙沙星加甲硝唑组为78%,而头孢曲松加甲硝唑组为81%,有资格转为口服治疗。临床成功率分别为98.9%和96.9%,在统计学上相当。所有患者的临床成功率,包括接受连续Ⅳ期治疗的患者,分别为90.6%和87.9%。 90%以上的患者实现了源控制。两组的细菌学根除率相似。头孢曲松联合甲硝唑组更常发生细菌并发症(例如手术部位感染,脓肿)。结论:环丙沙星联合甲硝唑Ⅳ口服治疗与头孢曲松联合甲硝唑统计学上等效。对于能够耐受肠内喂养的患者,转用环丙沙星联合甲硝唑的口服治疗与继续进行Ⅳ治疗一样有效和安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号